Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Galderma

< Previous 1 2 Next >
Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS
From Galderma
Via Business Wire
IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position
From Galderma
Via Business Wire
Galderma Announces Regulatory Approval for Restylane® SHAYPE™, a New Hyaluronic Acid Injectable Designed for Augmenting the Chin Region
From Galderma
Via Business Wire
TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously
From Galderma
Via Business Wire
Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines
From Galderma
Via Business Wire
Galderma Reports Record Net Sales of Over 3 B USD for the First Nine Months of 2023 With Strong Growth Momentum Across All Product Categories
From Galderma
Via Business Wire
Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
From Galderma
Via Business Wire
Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis
From Galderma
Via Business Wire
EADV 2023: Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology
From Galderma
Via Business Wire
Galderma announces progress with RelabotulinumtoxinA regulatory submissions
From Galderma
Via Business Wire
Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023, as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology
From Galderma
Via Business Wire
Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4
From Galderma
Via Business Wire
WCD 2023: Galderma to Present Extensive Data Demonstrating Enduring Commitment to Delivering Innovative Solutions in Dermatology
From Galderma
Via Business Wire
Galderma Raises Approximately USD 1 Billion for Newly Issued Shares in a Private Placement Round
From Galderma
Via Business Wire
Augmented Reality: Patient Experience Trumps Misconceptions Around Injectables
From Galderma
Via Business Wire
AMWC 2023: Data From Sculptra® Cheek Wrinkle and Alluzience® Star Studies Reinforce Strength of Galderma’s Broad Aesthetic Portfolio
From Galderma
Via Business Wire
AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant Impact on Prurigo Nodularis
From Galderma
Via Business Wire
Galderma Delivers Strong FY 2022 Growth Driven by Innovation and Commercial Performance
From Galderma
Via Business Wire
Galderma Announces the Launch of FACE by Galderma™ – a Game-Changing Augmented Reality Solution Helping Healthcare Professionals Grow Their Activity and Improve Patient Satisfaction
From Galderma
Via Business Wire
IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio
From Galderma
Via Business Wire
Galderma Announces Intention to Expand Manufacturing and Innovation Footprint in Asia-Pacific
From Galderma
Via Business Wire
Galderma Debuts The Sensitive Skincare Faculty, a Global Expert Group to Improve Understanding and Management of Sensitive Skin
From Galderma
Via Business Wire
GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress
From Galderma
Via Business Wire
Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio
From Galderma
Via Business Wire
Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis
From Galderma
Via Business Wire
Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation botulinumtoxinA (RelabotulinumtoxinA) for the Treatment of Glabellar Lines (frown) and Lateral Canthal Lines (crow’s Feet)
From Galderma
Via Business Wire
Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium
From Galderma
Via Business Wire
Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022
From Galderma
Via Business Wire
Galderma to Present New Clinical Data and High Patient Satisfaction Across Their Portfolio of Dermal Fillers, Collagen Biostimulators and Liquid Neuromodulators at AMWC 2022
From Galderma
Via Business Wire
Galderma to Highlight Latest Science and Innovation Across Its Product Portfolio at the 2022 AAD Annual Meeting
From Galderma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.